Physician profile
Candace D Koirth
NPI 1710082508
$10,806.89
in general payments reported to CMS, 2019-2025
62 companies · $2,343 in 2025
The $2,343 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,171 · 2022: $1,909 · 2023: $2,297 · 2024: $2,087 · 2025: $2,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,916 · Education: $811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,916.22 |
| Education | $810.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,934.59 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $673.65 | 2021-2025 | Enhertu, Calquence, Imfinzi |
| Genentech USA, INC. | $497.12 | 2021-2025 | Tecentriq, Polivy, Lunsumio |
| Glaxosmithkline, LLC. | $489.00 | 2021-2025 | Jemperli, Ojjaara, Zejula |
| Pfizer INC. | $472.45 | 2021-2025 | |
| Lilly USA, LLC | $413.86 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Merck Sharp & Dohme LLC | $402.21 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $391.00 | 2021-2025 | Imbruvica, Darzalex, Talvey |
| Celgene Corporation | $389.11 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Seagen INC. | $366.36 | 2021-2025 | Tukysa, Padcev |
| E.R. Squibb & Sons, L.L.C. | $289.46 | 2021-2025 | Opdivo, Opdualag |
| Emd Serono, INC. | $264.53 | 2021-2025 | Bavencio |
| Genzyme Corporation | $252.17 | 2021-2024 | |
| Daiichi Sankyo INC. | $251.88 | 2022-2025 | Enhertu, Vanflyta |
| Incyte Corporation | $242.37 | 2021-2025 | Monjuvi, Jakafi |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candace Koirth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.